GLP-1 Drugs and Testosterone: What Your Doctor Isn't Connecting

You are probably not the person who went to their doctor with a vague sense of something being wrong, got handed an Ozempic prescription, and never thought twice about it.

You are more likely the person who has spent years trying to understand why your energy is low, your body composition has shifted, and your labs keep coming back in the normal range while you feel anything but normal. You may already be on a GLP-1 drug, or you have been told you should be, and you are trying to figure out what it actually does to your hormonal system — not just your weight.

Why This Matters

That is a question most prescribers are not equipped to answer. The GLP-1 conversation in clinical settings is almost entirely about glycemic control and cardiovascular endpoints. What happens to testosterone, aromatase activity, and androgenic signaling when you run a GLP-1-driven caloric deficit is not part of the standard-of-care discussion. It should be.

What GLP-1 Drugs Actually Do to Testosterone — and How

The relationship between GLP-1 agonists and testosterone is indirect but real, and it runs through several mechanisms that compound on each other.

The most straightforward pathway is adipose tissue and aromatase. Fat cells, particularly visceral adipose tissue, express aromatase — the enzyme that converts testosterone into estrogen. The more visceral fat a man carries, the more active aromatase he has, and the more of his circulating testosterone gets converted to estradiol. This is why men with significant central adiposity often present with low testosterone and elevated estrogen simultaneously, even when their testes are producing normally. The production is not the problem. The conversion is.

GLP-1 drugs reduce visceral fat. That is one of their primary metabolic effects. As visceral adipose tissue contracts, aromatase activity falls, and less testosterone is lost to peripheral conversion. The result — documented in observational data and in a 2025 meta-analysis in Andrology — is a measurable rise in serum testosterone in men who lose significant weight on GLP-1 therapy, even without any direct hormonal intervention. The effect is not uniform across every agent and population, but the direction is consistent where meaningful fat loss occurs.

This is the mechanism that has generated interest in GLP-1 drugs as an indirect testosterone optimization tool. And the interest is not unreasonable. The biology is real. The question is what it actually means for a man who is trying to decide between GLP-1 therapy, TRT, or some combination of both.

A 2026 analysis in Endocrine Practice by Portillo-Canales and colleagues examined testosterone in men with obesity and type 2 diabetes on incretin therapy and found total testosterone rose from an average of 332 ng/dL to 399 ng/dL over treatment — a real recovery, achieved entirely through the body's own production. Worth being clear about the scale, though: TRT, which replaces the hormone directly rather than removing a suppressor, produces larger absolute increases by its nature. GLP-1-driven improvements are meaningful but indirect — they depend on fat loss occurring and the aromatase effect following from it.

This distinction matters clinically. A man with low testosterone, significant visceral adiposity, and no prior treatment has a reasonable case for trying GLP-1 therapy as a first-line approach — particularly if the primary driver of his hormonal suppression is aromatase activity rather than primary hypogonadism. If the fat comes off, the aromatase pressure comes off, and testosterone recovers through the body's own production.

A man with true primary or secondary hypogonadism — where the testes or the hypothalamic-pituitary axis are not producing adequately regardless of adipose burden — will not get there through GLP-1 therapy alone. The indirect mechanism only works if there is adequate endogenous production to be recovered. TRT remains the correct intervention when there is not.

The Aromatase Mechanism: What It Explains and What It Doesn't

Aromatase is the rate-limiting variable that most of the clinical GLP-1/testosterone literature is actually measuring, even when it does not say so directly. Understanding it clarifies both why some men see impressive testosterone recovery on GLP-1 therapy and why others do not.

Aromatase expression in adipose tissue is driven primarily by two factors: the volume of fat tissue and its inflammatory state. Visceral fat is more aromatase-active than subcutaneous fat — it is metabolically noisier, more inflamed at the cellular level, and more responsive to the conditions of insulin resistance and hyperinsulinemia that accompany obesity. This is why a man with predominantly visceral distribution (the apple shape, the high waist-to-hip ratio) tends to have worse androgenic suppression than a man carrying similar total fat mass with more subcutaneous distribution.

GLP-1 agonists reduce visceral fat more aggressively than subcutaneous fat in most trials. This is part of why the testosterone effect in GLP-1-treated men is real rather than an artifact of caloric restriction alone — the visceral specificity of GLP-1-driven fat loss hits the primary aromatase reservoir harder than generic dieting does.

The practical implication: if your testosterone suppression is being driven by visceral adiposity and aromatase activity, and you have intact gonadal function, GLP-1 therapy is doing something real for your hormonal environment. If your testosterone suppression is driven by primary hypogonadism, aging-related LH decline, or pituitary dysfunction, GLP-1 therapy will not rescue you hormonally even if it produces excellent metabolic results.

Labs to run before drawing conclusions:

• LH (luteinizing hormone). If LH is normal or elevated alongside low testosterone, the problem is at the gonadal level — primary hypogonadism. If LH is low or inappropriately normal given low testosterone, the signal is coming from above: secondary or mixed hypogonadism, or suppression by excess estrogen from aromatase activity.
• Estradiol (E2). High E2 relative to testosterone in an obese man points directly at aromatase activity as the driver. As visceral fat comes off on a GLP-1, watch E2 fall and testosterone rise. That is the aromatase mechanism working.
• SHBG (sex hormone binding globulin). SHBG determines how much of your total testosterone is biologically available as free testosterone. Insulin resistance suppresses SHBG, which paradoxically raises free testosterone fraction — but the absolute level is often still insufficient. As insulin sensitivity improves on GLP-1 therapy, SHBG may rise, which can reduce free testosterone even as total T improves. This is a nuance most prescribers miss entirely.

The Muscle Loss Problem and Why It Changes the Calculus

GLP-1-driven testosterone recovery does not occur in isolation. It happens inside a caloric deficit that, without active countermeasures, produces simultaneous lean mass loss. This is the tension the GLP-1/testosterone conversation in clinical settings consistently fails to hold.

The GLP-1 trial literature consistently shows that lean mass can account for roughly 25-40% of total weight lost on semaglutide — the STEP 1 trial body-composition substudy (Wilding et al., NEJM 2021) and a 2024 systematic review of semaglutide's effect on lean mass (Bikou et al., Expert Opin Pharmacother) both document the pattern, and it is the same evidence base behind our full muscle-loss guide. The 2026 NEJM review of GLP-1 receptor agonists (Rosen and Ingelfinger) flags loss of muscle and bone mass as a recognized cost of therapy.

For a man optimizing testosterone, this is the hidden cost. Skeletal muscle mass is not just a byproduct of testosterone signaling — it is also a driver of it. Muscle tissue expresses androgen receptors and contributes to insulin sensitivity, which in turn supports the gonadal environment. A man who loses 15 pounds of lean mass while gaining nominal testosterone through the aromatase mechanism has not made a net hormonal gain. He has traded one form of suppression for another.

What the Decision Tree Actually Looks Like

If you are trying to decide how GLP-1 therapy fits into your hormonal picture, here is the clinical logic.

Run these labs first:

• Morning total testosterone and free testosterone (8-10am draw, two separate mornings if the first is unexpectedly low)
• LH and FSH
• Estradiol (sensitive assay)
• SHBG
• IGF-1
• Fasting insulin and glucose

If total T is 300-500, estradiol is elevated, LH is normal or low, and you carry significant visceral fat: GLP-1 therapy is a reasonable first-line approach. The aromatase mechanism is your likely driver, visceral fat is the target, and there is a real case for watching testosterone recover as the fat comes off. Do not add TRT before giving this pathway 12-16 weeks to produce data.

If total T is below 300 with appropriately elevated LH: Primary hypogonadism. GLP-1 therapy will help your metabolic picture but will not rescue your testosterone through the aromatase pathway alone. TRT is indicated and appropriate alongside GLP-1 if you have both conditions.

If total T is below 300 with low or inappropriately normal LH: Secondary hypogonadism. The signal is not reaching the gonads. This could be aromatase-driven suppression of hypothalamic GnRH (estrogen feedback), or it could be independent pituitary or hypothalamic dysfunction. A GLP-1 trial is reasonable if visceral fat is significant — but the LH suppression pattern warrants closer monitoring. If LH does not recover as fat comes off, this is not aromatase; it is a different problem.

On the muscle side, regardless of which path you are on:

• Protein at 1.6-2.2 g/kg lean mass per day
• Resistance training at minimum twice weekly, progressive overload
• Creatine monohydrate 3-5g daily
• DEXA at baseline, repeat at 12 weeks

The testosterone recovery from GLP-1 is meaningful. The lean mass loss is also real. Hold both, act on both. For the lifestyle levers that support endogenous production, see our guide to natural testosterone optimization.

Caveats and When to Escalate

This article is for generally healthy adults who are trying to understand their hormonal picture in the context of GLP-1 therapy. There are specific situations that require clinical involvement beyond what any article can provide.

Active cancer or hormone-sensitive conditions: Do not interpret any of this in the context of prostate cancer, breast cancer in women taking GLP-1s, or any other hormone-sensitive malignancy without your oncologist in the room. Testosterone optimization in active malignancy is a clinical decision, not a protocol.

Existing TRT: If you are already on TRT and starting a GLP-1, expect your exogenous testosterone to remain stable but your endogenous production to be suppressed (as it is by design on TRT). The aromatase mechanism described here applies primarily to men with endogenous production. As visceral fat comes off, your E2 may fall on TRT — monitor estradiol at 12 weeks and adjust aromatase inhibitor dosing if applicable.

Rapid or unexpected testosterone decline on GLP-1: If testosterone falls while you are losing weight on a GLP-1 (which can happen if protein is severely restricted and lean mass loss is substantial), that is not the aromatase mechanism failing — that is the metabolic stress of aggressive caloric restriction overwhelming the hormonal recovery. Address lean mass preservation first.

Fertility considerations: GLP-1 therapy's effects on spermatogenesis are not well-characterized at this point. If fertility is a consideration, this is an active question to raise with a reproductive endocrinologist. For more on the broader peptide and hormone landscape, see our peptides guide hub.

Key Takeaways

• GLP-1 drugs can raise testosterone, but indirectly — by reducing visceral fat and the aromatase activity that converts testosterone to estradiol.
• The effect only works if you have intact gonadal function and your suppression is aromatase-driven. Primary or true secondary hypogonadism will not be rescued by GLP-1 therapy alone.
• A 2026 Endocrine Practice analysis found total testosterone rose from 332 to 399 ng/dL on incretin therapy — real, but smaller in absolute terms than TRT, which replaces the hormone directly.
• Run LH, estradiol, SHBG, and free testosterone before drawing conclusions; SHBG can rise as insulin sensitivity improves, lowering free testosterone even as total T climbs.
• Lean mass can account for 25-40% of total weight lost on semaglutide — testosterone recovery does not justify skipping muscle-preservation work.
• Protect muscle with adequate protein, resistance training, creatine, and DEXA monitoring regardless of which hormonal path you are on.
• Escalate to clinical care for hormone-sensitive cancers, existing TRT, unexpected testosterone decline, or fertility concerns.

References

1. Portillo-Canales E, et al. Incretin-based therapy and testosterone recovery in men with obesity and type 2 diabetes. Endocr Pract. 2026. Link
2. GLP-1 receptor agonists and serum testosterone in men: a systematic review and meta-analysis. Andrology. 2025. Link
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. Link
4. Bikou A, Dermiki-Gkana F, Penteris M, et al. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. 2024;25(5):611-619. Link
5. Rosen CJ, Ingelfinger JR. GLP-1 receptor agonists — a review of efficacy, safety, and unanswered questions. N Engl J Med. 2026. Link